Tantangan dan Perkembangan Vaksin HIV (Human Immunodeficiency Virus)

Antiretroviral therapy (ART) is the first treatment for HIV/AIDS cases, it known to improve patient's quality of life, but cannot cure HIV infection. a virus that infects CD4+, this infection can cause cell death. Vaccines are an effort prevent infection, until now vaccine has not been found, systematic review was conducted find out challenges and developments vaccines date, challenge developing ability induce Broadly Neutralizing Antibodies (bNAbs). The protein subunit platform developed Env trimeric mock design be able expose bNAbs epitope, from various designs proven successful, methods stabilization purification strategies greatly affect protein. New have emerged with more modern methods, mRNAs enhancing expression self-amplifying alphavirus-derived ones shown potential in preclinical assay GT-based 60mer eOD-GT8 promote GC response elicit somatic hypermutation, resulting VRC01 class bnAbs which antibodies most widely used HIV-1 efficacy. In addition, targeting dendritic cells mRNA transfection as therapeutic offers HIV-specific T responses, research on HIV-1-infected patients still process optimizing stronger longer-lasting immune response, establishing control period. length viral replication along eliminating reservoir factors preventing re-emergence, two influential, namely general condition patient (genetic clinical status) product.